Global clinical trials for the treatment of TB with thioridazine

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 99-103

  Boeree, Martin J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Global clinical trials; Therapy of xdr tb; Thioridazine

Indexed keywords

BIOLOGICAL MARKER; PHENOTHIAZINE DERIVATIVE; RIFAMPICIN; SILA 421; STREPTOMYCIN; THIORIDAZINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COMPASSIONATE USE; DOSE RESPONSE; DRUG APPROVAL; DRUG DESIGN; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; SHORT COURSE THERAPY;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PATENTS AS TOPIC; RISK ASSESSMENT; THIORIDAZINE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79959966664     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064533     Document Type: Article

References (30)

1. WHO. www.who.int/tb/challenges/xdr/en/index.html. 2011. Ref Type: Internet Communication
2. TB alliance. www.tballiance.org. 2011. Ref Type: Internet Communication
3. Gogerty, J.H. Enhanced learning ability by use of thioridazine.US3879552(1973).
4. Hsu, T.A., Taipei, T.W. Treatment of coronavirus. US7544712 (2009).
5. Joachim, R. Organic compounds. US4387086 (1983).
6. Martins M, Viveiros M, Ramos J, Couto I, Molnar J, Boeree M, et al. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int J Antimicrob Agents 2009; 33(5): 479-82.
7. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47(3): 917-22.
8. Vanriet, D.D., Lee, R.B., Coffin, W.A. MDR efflux pumps.WO179257 (2001).
9. De Souza N.J., Patel M.V., Gupte S.V., Upadhyay D.J., Chaturvedi N.C., Bhawsar S.B., Nair, S.C., Jafri, M.A., Khorakiwala, H.F. Inhibitors of cellular efflux pumps of microbes. AU8009101 & US2002177559 (2002).
10. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van SD. Thioridazine cures extensively drug-resistant tuberculosis (XDRTB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35(6): 524-6.
11. Bate AB, Kalin JH, Fooksman EM, Amorose EL, Price CM, Williams HM, et al. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. Bioorg Med Chem Lett 2007; 17(5): 1346-8.
12. Kim, L., Peichung, H. Drug discovery and increased potency of antiseptics and disinfectans based on high extracellular pH, the disablement of cellular efflux pumps, and the unexpected synergism there between.US2003118541 (2003).
13. Amaral L, Molnar J. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent as new use. Recent Pat Antiinfect Drug Discov 2010; 5(2): 109-14.
14. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev 2000; (2): CD001362.
15. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010; 16(3):186-93.
16. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, et al. Biomarkers and diagnostics for tuberculosis: Progress, needs, and translation into practice. Lancet 2010; 375(9729):1920-37.
17. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17(3): 225-8.
18. Teisseyre A, Michalak K. The voltage- and time-dependent blocking effect of trifluoperazine on T lymphocyte Kv1.3 channels. Biochem Pharmacol 2003; 65(4): 551-61.
19. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 2007; 59(6): 1237-46.
20. Xie Z, Siddiqi N, Rubin EJ. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2005; 49(11): 4778-80.
21. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 2010;5(4): e10069.
22. Abbate E, Vescoso M, Natiello M, Garcia A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacables epidemiologicos, bacteriologicos, terapeuticos y evolotivos. Revista Argentina de Medicina Respiratoria 2007; 1:19-25.
23. Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 2009; 16(21): 2661-805.
24. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: Challenges and opportunities. Int J Tuberc Lung Dis 2010; 14(5): 528-37.
25. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4(11): e292.
26. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) 2008; 88 (Suppl 1): S85-S92.
27. fda. www.fda.gov. 2011. Ref Type: Internet Communication
28. PanACEA. www.panacea-tb.sharesrvr.com. 2011. Ref Type: Internet Communication
29. RESISTTB. http://www.resisttb.org/. 2011. Ref Type: Internet Communication
30. EDCTP. http://www.edctp.org/. 2011. Ref Type: Internet Communication